Community data Updated 2 months ago

Bicalutamide

Hormonal Chemotherapy Prescription

Indications

Cancer

Bicalutamide is indicated, in combination with a luteinizing hormone-releasing hormone (LHRH) analogue, for the treatment of Stage D2 metastatic carcinoma of the prostate.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Bicalutamide belongs to a class of medicines called non-steroidal androgen receptor inhibitors. It works by attaching to androgen receptors within the target tissue, thereby blocking the action of androgens (male hormones) at those sites. Prostate cancer is generally androgen-sensitive, meaning it tends to respond to treatments that either counteract the effect of androgens or reduce the amount of androgen available in the body.

Pregnancy & Breastfeeding

Bicalutamide should never be used during pregnancy, as it may harm the developing baby. It is not intended for use in women at all, and no human studies exist on its use during pregnancy.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: When bicalutamide is given together with an LHRH analogue, the usual adult dose is one 50 mg tablet taken once a day, in the morning or evening, with or without food. Pediatric use: The safety and effectiveness of bicalutamide in pediatric patients have not been established. Hepatic impairment: Bicalutamide is broken down extensively by the liver, so it should be used with caution in patients with moderate-to-severe hepatic impairment.